Compare CCNE & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CCNE | LTGO |
|---|---|---|
| Founded | 1865 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 1995 | 2026 |
| Metric | CCNE | LTGO |
|---|---|---|
| Price | $33.38 | $14.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $38.00 | ★ $52.25 |
| AVG Volume (30 Days) | 116.6K | ★ 359.2K |
| Earning Date | 10-29-2026 | 11-19-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ 4.18 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.41 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | $18.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.90 | $14.60 |
| 52 Week High | $36.17 | $25.93 |
| Indicator | CCNE | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 44.24 | 31.16 |
| Support Level | $32.84 | N/A |
| Resistance Level | $35.06 | $20.49 |
| Average True Range (ATR) | 0.62 | 1.23 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 36.51 | 1.69 |
CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.